Somewhere in the last thirty years, a story about the brain became common knowledge: “depression is a chemical imbalance." Serotonin is low; a pill corrects the deficit. The logic is clean, the narrative satisfying, and the number of people who have heard some version of it is enormous. The problem is that the evidence never quite supported it.
In 2023, a group of scientists reviewed decades of research on serotonin and depression and found no consistent evidence that people with depression have lower serotonin levels or activity than those without it [1].
This article goes past the serotonin headline and into what current neuroscience actually shows: a set of biological systems, including stress, inflammation, brain plasticity, and genetics, that interact in ways that are far more interesting, and far more actionable, than a leaky neurotransmitter tank.
Why the “Low Serotonin” Theory Falls Short
The serotonin hypothesis wasn't invented out of thin air. It emerged from real observations in the 1960s, when researchers noticed that drugs affecting monoamine neurotransmitters (serotonin, dopamine, norepinephrine) also affected mood. It gained enormous traction in the 1990s with the rise of selective serotonin reuptake inhibitors (SSRIs) like Prozac® [2]. The logic felt intuitive: if a drug that raises serotonin helps depression, then depression must involve low serotonin.
The problem is that intuitive logic isn't always right. SSRIs raise serotonin within hours, but their antidepressant effects take weeks to emerge, a timing mismatch that suggests something more complex is going on downstream. And when researchers tried to directly test the low-serotonin hypothesis by measuring serotonin metabolites in blood and cerebrospinal fluid, imaging serotonin receptors, or experimentally depleting serotonin in healthy people, the results were consistently inconsistent [1].
That doesn't mean serotonin is irrelevant. It plays a genuine role in mood regulation, emotional processing, and social behavior, but it's one instrument in a very large orchestra.
A Better Model: Depression as a Whole-System Condition
Think of your brain and body less like a single engine with one thing that can go wrong, and more like an interconnected infrastructure, where multiple systems run simultaneously, and each one affects the others. Depression, in this view, is what happens when several of those systems end up under prolonged strain at once.
Modern research increasingly supports this picture. Depression is better understood as a multifactorial, heterogeneous condition, meaning it doesn't have one cause and it doesn't look the same in every person [3]. Some people's depression is driven primarily by a dysregulated stress response; others show significant immune activation; others have altered brain circuit connectivity with reduced plasticity. Most show some combination, and this heterogeneity helps explain why the same treatment works powerfully for one person and barely at all for another.
Four interacting systems appear most consistently in the research. The first is the stress system, built around the hypothalamic-pituitary-adrenal axis. The second is the immune system, through inflammatory signaling. The third is neuroplasticity, or the brain's capacity to rewire itself. The fourth is genetics and epigenetics, which shape how susceptibility is inherited and how the environment leaves lasting marks on gene expression. What follows is a closer look at each one.
The Stress Response: When the alarm won't turn off
The hypothalamic-pituitary-adrenal axis (HPA axis) is one of the body's main stress-response circuits, and it works a lot like a smoke alarm. When you encounter a threat, your hypothalamus signals your pituitary gland, which signals your adrenal glands to release cortisol, a hormone that mobilizes energy, sharpens alertness, and prepares you to respond. When the threat passes, a feedback loop turns the alarm off.
In people with depression, that feedback loop often fails. The alarm keeps firing. Chronic stress leads to sustained cortisol elevation, which over time disrupts the very receptors that are supposed to silence the response, a phenomenon researchers describe as HPA axis dysregulation [4]. These abnormalities appear particularly consistent in melancholic subtypes of depression, where cortisol dysregulation may directly impair cognitive function and emotional regulation [5].
The cumulative wear-and-tear on biological systems from sustained stress even has a name: allostatic load [6]. Think of it as the bill that arrives after months of running every appliance in the house at full capacity: the circuits hold up for a while, then things start to fail in unpredictable ways.
The Immune System: Inflammation, an unexpected player in mood
The second alarm system that tends to get stuck is the immune system. A growing body of evidence links elevated inflammatory markers to depressive symptoms [7]. Researchers examining cerebrospinal fluid, brain imaging, and post-mortem tissue found that two of the most consistently implicated, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), are elevated in the central nervous system of people with major depressive disorder [8].
One of the more elegant explanatory frameworks here is the concept of sickness behavior. When your immune system detects infection or tissue damage, it produces cytokines, signaling molecules that make you feel tired, socially withdrawn, and disinterested in food or pleasure. Evolutionarily, this makes sense: when you're fighting an infection, resting and avoiding social contact is adaptive. The problem is that in the context of chronic psychological stress or trauma, the immune system can activate similar responses without a pathogen in sight, producing what looks and feels a great deal like depression [7,9].
Importantly, elevated inflammation characterizes a subset of people with depression, not all of them [8]. This is one reason the same treatment doesn't work for everyone, and it points toward the possibility that inflammatory biomarkers could eventually help personalize treatment approaches. Inflammation appears to specifically disrupt brain circuits involved in motivation and reward, which may help explain anhedonia, the inability to feel pleasure, that is so often central to depression [10].
Also, the stress system and the immune system do not operate in isolation. Sustained cortisol elevation can promote inflammation, and inflammation can further dysregulate the HPA axis, creating a feedback loop that compounds the effect on mood, energy, and cognition [7].
Neuroplasticity: When the brain gets stuck in patterns
Neuroplasticity refers to the brain's capacity to change: to form new connections, strengthen useful pathways, and prune ones that are no longer needed. It's what allows learning, recovery from injury, and adaptation to new circumstances. A healthy brain is, in a sense, a flexible brain.
Chronic stress and depression are associated with reduced plasticity in key brain regions, particularly the hippocampus (involved in memory and stress regulation) and the prefrontal cortex (involved in decision-making, emotional regulation, and perspective-taking). Under sustained stress, these areas can lose synaptic connections and show structural changes that appear to contribute to the cognitive rigidity, rumination, and difficulty shifting mental states that characterize depression [11].
A worn footpath through grass is a useful image here: walk the same route every day, and it becomes deep and hard to leave, even when a better route exists. Depressive thought patterns work similarly: repeated activation of stress circuits, combined with reduced plasticity, can make it progressively harder for the brain to access other states.
Central to the neuroplasticity story is brain-derived neurotrophic factor (BDNF), a protein that supports neuron survival, synaptic growth, and the brain's capacity to adapt. BDNF levels are frequently reduced in people with depression, and chronic stress is a reliable suppressor of BDNF production [12].
Genetics and Epigenetics: Why there's no single cause, and why that's actually good news
Depression runs in families, but not simply or predictably. There is no single "depression gene". Instead, genome-wide association studies (large-scale analyses that scan hundreds of thousands of genetic variants across populations) have identified over 100 genetic variants associated with depression, each contributing a small amount of risk, none determining outcome on its own [13]. Depression is polygenic, meaning many genes interact with each other and with environmental context to shape susceptibility.
This is where epigenetics becomes especially important. Epigenetics refers to changes in how genes are expressed, turned up or down, without altering the underlying DNA sequence itself. Think of it as the volume dial on a gene: the sequence doesn't change, but how loudly it gets read does. Environmental experiences, including chronic stress, trauma, early adversity, poor sleep, and social isolation, can leave molecular marks on the genome that influence which genes get activated and to what degree [14]. These marks can persist long after the original stress has passed, which may partly explain why early-life adversity is such a robust predictor of adult depression risk.
Research into the epigenetic landscape of major depressive disorder has found consistent evidence of altered molecular marks on stress-related genes, changes that affect the HPA axis, neuroplasticity, and inflammatory signaling simultaneously [15]. In other words, epigenetic changes don't target one system in isolation; they tend to shift the entire biological context in which depression operates.
What makes all of this less daunting than it sounds is that the biological context of depression is not static. The same environmental forces that can push these systems toward dysfunction (chronic stress, early adversity, social isolation) can, under different conditions, push them in the other direction [6].
Where Serotonin Fits (Without Overcorrecting)
None of this means serotonin is irrelevant. It plays a real and important role in mood regulation, emotional processing, and social behavior. A more accurate framing is that serotonin acts as a modulator across many of the systems described above: it interacts with HPA axis function, influences inflammatory signaling, and is embedded in the brain circuits governing reward and stress response [2].
SSRIs can still be genuinely helpful for many people, not because they refill the serotonin tank, but because sustained changes in serotonin signaling appear to trigger downstream effects on neuroplasticity, BDNF expression, and circuit connectivity [11]. Those changes take time to develop, which is why antidepressant effects emerge over weeks rather than hours, even though serotonin levels rise within the first doses. The drug acts fast; the brain adapts slowly.
Understanding serotonin as part of a network, rather than the whole story, also helps explain why SSRIs work well for some people and not others, why response takes weeks rather than hours, and why combining medication with therapy or lifestyle change tends to produce better outcomes than any single approach alone [3].
What This Means for Treatment and Why It's Not One-Size-Fits-All
If depression involves multiple interacting biological systems rather than a single deficiency, then treatment logically benefits from a multi-layered approach, and the evidence supports exactly that:
- Medication can be a meaningful part of treatment for many people, particularly when depression is moderate to severe. But it works best understood as one tool among several, not a complete solution in isolation.
- Psychotherapy, particularly cognitive behavioral therapy (CBT), helps retrain thought patterns and may support neuroplasticity by building new associative pathways. A meta-analysis of 115 randomized studies confirmed CBT as an effective treatment for adult depression, with effects comparable to pharmacotherapy and stronger when combined with it [16].
- Lifestyle factors including exercise, sleep quality, social connection, and stress management have well-documented effects on HPA axis regulation, inflammatory signaling, BDNF levels, and epigenetic expression. These aren't soft add-ons; they work through the same biological mechanisms that pharmaceutical treatments target [6,17].
Personalization matters here more than in almost any other area of health. Because depression is heterogeneous, different systems are dominant in different people; what works powerfully for one person may do very little for another [3]. The emerging field of precision psychiatry aims to match treatments to individual biological profiles, including inflammatory markers, genetic variants, and neuroimaging data [18]. Not there yet clinically, but the direction is clear, and the rationale is sound.
Conclusion: From One Chemical to a Complex System
The chemical imbalance story of depression served a purpose. It made an invisible illness feel tangible and helped shift it out of the realm of moral failure. But science has moved on, and the picture that has emerged is considerably richer.
Depression is better understood as a condition that arises when multiple biological systems — the stress response, immune signaling, brain plasticity, and gene expression — interact under pressure in ways that tip mood, cognition, and motivation toward a persistent dark state. Serotonin is part of this story, but only a part.
The more nuanced view isn't discouraging. It's actually the opposite. A multi-system condition offers multiple points of intervention. Complexity, in this case, means options.
References
1. Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2023;28:3243-3256. doi:10.1038/s41380-022-01661-0
2. Andrews PW, Bharwani A, Lee KR, Fox M, Thomson JA. Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response. Neurosci Biobehav Rev. 2015;51:164-188. doi:10.1016/j.neubiorev.2015.
3. Fried EI, Flake JK, Robinaugh DJ. Revisiting the theoretical and methodological foundations of depression measurement. Nat Rev Psychol. 2022;1:358-368. doi:10.1038/s44159-022-00050-2
4. Keller J, Gomez R, Williams G, et al. HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition. Mol Psychiatry. 2017;22(4):527-536. doi:10.1038/mp.2016.120
5. Juruena MF, Bocharova M, Agustini B, Young AH. Atypical depression and non-atypical depression: Is HPA axis function a biomarker? A systematic review. J Affect Disord. 2018;233:45-67. doi:10.1016/j.jad.2017.09.052
6. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007;87(3):873-904. doi:10.1152/physrev.00041.2006
7. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34. doi:10.1038/nri.2015.5
8. Enache D, Pariante CM, Mondelli V. Markers of central inflammation in major depressive disorder: A systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun. 2019;81:24-40. doi:10.1016/j.bbi.2019.06.015
9. Khandaker GM, Dantzer R, Jones PB. Immunopsychiatry: important facts. Psychol Med. 2017;47(13):2229-2237. doi:10.1017/S0033291717000745
10. Felger JC. Imaging the Role of Inflammation in Mood and Anxiety-related Disorders. Curr Neuropharmacol. 2018;16(5):533-558. doi:10.2174/
11. Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22(3):238-249. doi:10.1038/nm.4050
12. Castren E, Monteggia LM. Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action. Biol Psychiatry. 2021;90(2):128-136. doi:10.1016/j.biopsych.2021.
13. Howard DM, Adams MJ, Clarke TK, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22(3):343-352. doi:10.1038/s41593-018-0326-7
14. Klengel T, Binder EB. Epigenetics of Stress-Related Psychiatric Disorders and Gene x Environment Interactions. Neuron. 2015;86(6):1343-1357. doi:10.1016/j.neuron.2015.05.
15. Yuan M, Yang B, Rothschild G, et al. Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential. Signal Transduct Target Ther. 2023;8:309. doi:10.1038/s41392-023-01519-z
16. Cuijpers P, Berking M, Andersson G, Quigley L, Kleiboer A, Dobson KS. A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Can J Psychiatry. 2013;58(7):376–385. doi:10.1177/070674371305800702
17. Kandola A, Ashdown-Franks G, Hendrikse J, Sabiston CM, Stubbs B. Physical activity and depression: Towards understanding the antidepressant mechanisms of physical activity. Neurosci Biobehav Rev. 2019;107:525–539. doi:10.1016/j.neubiorev.2019.
18. Kajumba MM, Kakooza-Mwesige A, Nakasujja N, Koltai D, Canli T. Treatment-resistant depression: molecular mechanisms and management. Mol Biomed. 2024;5(1):43. doi:10.1186/s43556-024-00205-y
